Candida Auris Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Candida Auris Epidemiology Forecast Report Coverage

Expert Market Research's “Candida Auris Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Candida Auris. It projects the future incidence and prevalence rates of Candida Auris cases across various populations. The study covers age, gender, and type as major determinants of the Candida Auris population. The report highlights patterns in the prevalence of Candida Auris overtime and projects future trends based on multiple variables.

Candida Auris Understanding: Disease Overview

Candida auris (C. auris), also referred to as Candidozyma auris, is an emerging multidrug-resistant yeast that causes healthcare-associated colonization and invasive fungal infection. Unlike most Candida species, C. auris can persist for prolonged periods on patients, environmental surfaces and medical equipment, facilitating transmission within healthcare facilities. Patients may remain asymptomatically colonized on the skin while serving as reservoirs for transmission or may develop invasive infection involving the bloodstream and other normally sterile sites. The organism is particularly important because it can be resistant to multiple classes of antifungal agents, can be difficult to identify using conventional yeast-identification systems and is associated with outbreaks among critically ill and medically complex patients. WHO classifies C. auris as a critical-priority fungal pathogen.

Key Report Insights

Candida Auris Epidemiology Perspective

The Candida Auris epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Candida Auris epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Candida Auris and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Type-Specific Disease Burden and Epidemiology Analysis

Read more about this report - Request a Free Sample

Country-wise Candida Auris Epidemiology

The Candida Auris epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The primary epidemiological gap in C. auris is incomplete measurement of the distinction between colonization and invasive disease. Colonized patients frequently have no symptoms but can carry and transmit the organism, while invasive disease represents a clinically smaller but substantially more consequential subset. England's 2023–2025 data, in which 84% of detected patients were colonized and 14% were invasive, illustrate how strongly the measured burden depends on whether active screening accompanies clinical surveillance. A second gap is inconsistent national surveillance. ECDC reported 1,346 cases across 18 EU/EEA countries in 2023 but explicitly characterized these data as an underestimate because systematic surveillance was not implemented uniformly across Europe. Similar limitations apply in India and other countries where laboratory identification, reporting and screening vary substantially between institutions. Consequently, absence of reported cases cannot reliably be interpreted as absence of transmission.

Candida Auris: Treatment Overview

The management of Candida auris primarily focuses on distinguishing colonization from clinical infection, treating invasive disease promptly, determining antifungal susceptibility, managing invasive devices and applying sustained infection-control precautions. CDC specifically recommends not treating patients who are colonized but have no signs or symptoms of infection, because antifungal treatment does not eradicate colonization reliably and exposes patients to unnecessary therapy. For adults and children older than two months with clinical C. auris infection, CDC currently recommends an echinocandin as initial therapy, using anidulafungin, caspofungin or micafungin according to patient characteristics and dosing requirements. Because C. auris may develop resistance during treatment, clinicians should monitor clinical response and obtain susceptibility testing.

Key Questions Answered

• What is the current and projected burden of Candida Auris across the 8 major markets?
• Which countries across the 8 major markets account for the highest Candida Auris patient populations and fastest growth rates?
• What is the diagnosed versus undiagnosed patient population of Candida Auris across key countries in the 8 major markets?
• Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of Candida Auris across the 8 major markets?
• What are the major drivers contributing to the increasing burden of Candida Auris across the 8 major markets?
• How do major comorbidities and risk factors influence Candida Auris epidemiology trends across the 8 major markets?
• What are the regional trends in advanced disease progression, treatment uptake, and patient management of Candida Auris across the 8 major markets?
• Which patient segments represent the highest unmet clinical need in the Candida Auris landscape across the 8 major markets?
• Which therapeutic areas linked to Candida Auris are expected to witness the strongest growth opportunities across the 8 major markets?
• How is the Candida Auris epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
• Which countries across the 8 major markets offer the most attractive market opportunities based on Candida Auris epidemiology and healthcare infrastructure?
• Which epidemiological trends are expected to influence future drug development and market access strategies for Candida Auris across the 8 major markets?

Scope of the Candida Auris Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Candida Auris based on several factors.
• Candida Auris Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The Candida Auris report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Fungal Infections Market

Invasive Fungal Infections Epidemiology Forecast